E6888
依那普利 马来酸盐
≥98% (HPLC), ACE inhibitor, powder
别名:
( S )-N-[1-（乙氧基羰基）-3-苯基丙基]-Ala-Pro 马来酸盐
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C20H28N2O5 · C4H4O4
化学文摘社编号:
分子量:
492.52
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
EC Number:
278-375-7
产品名称
依那普利 马来酸盐, powder, ≥98% (HPLC)
InChI
1S/C21H30N2O5.C4H4O5/c1-3-28-19(24)14-17(12-11-16-8-5-4-6-9-16)22-15(2)20(25)23-13-7-10-18(23)21(26)27;5-3(6)1-2-4(7)9-8/h4-6,8-9,15,17-18,22H,3,7,10-14H2,1-2H3,(H,26,27);1-2,8H,(H,5,6)/b;2-1-/t15-,17-,18-;/m0./s1
InChI key
UQKQUZOIQFOJOI-KJHLASMFSA-N
SMILES string
C[C@@H](C(N1[C@H](C(O)=O)CCC1)=O)N[C@H](CC(OCC)=O)CCC2=CC=CC=C2.O=C(OO)/C=C\C(O)=O
form
powder
color
white to off-white
solubility
methanol: ≥50 mg/mL, clear, colorless to yellow
originator
Merck & Co., Inc., Kenilworth, NJ, U.S.
Quality Level
assay
≥98% (HPLC)
正在寻找类似产品? 访问 产品对比指南
Application
依那普利马来酸盐用于：
- 降低白蛋白排泄率（AER）和肾小球病变。
- 研究依那普利预处理对心肌损伤的影响
- 研究其缓解放射性肺损伤的有效剂量和时间。
Biochem/physiol Actions
一种长效血管紧张素转换酶抑制剂。
Features and Benefits
该化合物是由Merck & Co., Inc., Kenilworth, NJ, U.S.开发的。想要浏览其他由制药公司开发的化合物以及已批准药物/候选药物清单， 请单击此处。
这种化合物是ADME毒性研究的特色产品。点击此处发现更多特色ADME毒性产品。在sigma.com/discover-bsm可了解更多关于生物活性小分子的其他研究领域。
General description
依那普利是血管紧张素转换酶抑制剂。用于治疗心力衰竭和高血压。
signalword
Warning
hcodes
Hazard Classifications
Repr. 2
存储类别
11 - Combustible Solids
wgk
WGK 2
ppe
Eyeshields, Gloves, type N95 (US)
Lufei Hu et al.
PloS one, 17(1), e0261000-e0261000 (2022-01-28)
Diabetic nephropathy is associated with endothelial dysfunction and oxidative stress, in which the nitric oxide-soluble guanylate cyclase-cyclic guanosine monophosphate (NO-sGC-cGMP) signaling pathway is impaired. We hypothesize that sGC stimulator Compound 1 can enhance NO signaling, reduce proteinuria in a diabetic
Association of Proteinuria with Urinary Concentration Defect in Puromycin Aminonucleoside Nephrosis.
Chor Ho Jo et al.
Electrolyte & blood pressure : E & BP, 18(2), 31-39 (2021-01-08)
Puromycin aminonucleoside (PA) can induce nephrotic syndrome in rats, and proteinuria is an important mediator of tubulointerstitial injury in glomerulopathy. We assumed that glomerular proteinuria may affect tubular function, such as urinary concentration, and investigated whether a urinary concentration defect
Enalapril
Todd PA and Heel RC
Drugs, 31(3), 198-248 (1986)
Urinary peptidomics provides a noninvasive humanized readout of diabetic nephropathy in mice
Klein J, et al.
Kidney International, 90(5), 1045-1055 (2016)
Guang Liu et al.
American journal of physiology. Renal physiology, 319(4), F697-F711 (2020-09-01)
Praliciguat, a clinical-stage soluble guanylate cyclase (sGC) stimulator, increases cGMP via the nitric oxide-sGC pathway. Praliciguat has been shown to be renoprotective in rodent models of hypertensive nephropathy and renal fibrosis. In the present study, praliciguat alone and in combination
商品
Discover Bioactive Small Molecules for ADME/Tox
相关内容
Product Information Sheet
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持